Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,100
  • Shares Outstanding, K 32,100
  • Annual Sales, $ 57,060 K
  • Annual Income, $ 9,990 K
  • 60-Month Beta 1.20
  • Price/Sales 45.56
  • Price/Cash Flow 1.28
  • Price/Book 1.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/20
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +65.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.18 +19.07%
on 01/29/20
1.79 -21.51%
on 02/05/20
-0.16 (-10.48%)
since 01/24/20
3-Month
1.18 +19.07%
on 01/29/20
1.79 -21.51%
on 02/05/20
-0.12 (-7.57%)
since 11/26/19
52-Week
1.13 +24.07%
on 06/28/19
2.46 -42.89%
on 02/27/19
-0.47 (-24.87%)
since 02/26/19

Most Recent Stories

More News
Summit Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Summit Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

SMMT : 1.40 (-2.43%)
Top Ranked Momentum Stocks to Buy for October 22nd

Top Ranked Momentum Stocks to Buy for October 22nd

SMMT : 1.40 (-2.43%)
NRG : 35.05 (-2.99%)
LAD : 124.51 (-1.88%)
CMRE : 6.55 (+2.02%)
Can the Rally in Summit Therapeutics Shares Continue?

As of late, it has definitely been a great time to be an investor Summit Therapeutics.

SMMT : 1.40 (-2.43%)
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies...

SMMT : 1.40 (-2.43%)
CDTX : 2.90 (+0.69%)
ETTX : 5.02 (+0.28%)
ITRM : 2.93 (-6.98%)
MLNT : 0.4400 (-12.00%)
NBRV : 1.37 (-2.84%)
PRTK : 4.32 (+20.00%)
SCYX : 0.97 (-1.02%)
X-Biotix Therapeutics Joins Antimicrobials Working Group

The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur...

SMMT : 1.40 (-2.43%)
CDTX : 2.90 (+0.69%)
CFRX : 9.93 (-9.15%)
ETTX : 5.02 (+0.28%)
ITRM : 2.93 (-6.98%)
MLNT : 0.4400 (-12.00%)
NBRV : 1.37 (-2.84%)
PRTK : 4.32 (+20.00%)
SCYX : 0.97 (-1.02%)
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies...

SMMT : 1.40 (-2.43%)
CDTX : 2.90 (+0.69%)
CFRX : 9.93 (-9.15%)
ETTX : 5.02 (+0.28%)
ITRM : 2.93 (-6.98%)
MLNT : 0.4400 (-12.00%)
NBRV : 1.37 (-2.84%)
PRTK : 4.32 (+20.00%)
SCYX : 0.97 (-1.02%)
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for...

MTFB : 0.10 (-4.63%)
SMMT : 1.40 (-2.43%)
CDTX : 2.90 (+0.69%)
CFRX : 9.93 (-9.15%)
ETTX : 5.02 (+0.28%)
ITRM : 2.93 (-6.98%)
MLNT : 0.4400 (-12.00%)
NBRV : 1.37 (-2.84%)
PRTK : 4.32 (+20.00%)
SCYX : 0.97 (-1.02%)
Keysight Technologies Displays Design and Test Solutions to Accelerate Microwave and Radio Frequency Innovation at IMS 2019

Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that helps enterprises, service providers and governments accelerate innovation to connect and secure the world, along...

SMMT : 1.40 (-2.43%)
KEYS : 94.07 (+0.44%)
Detailed Research: Economic Perspectives on Patterson-UTI Energy, Take-Two Interactive Software, DXC Technology, Ingevity, Summit Therapeutics, and Kinsale Capital Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Patterson-UTI Energy, Inc....

PTEN : 6.03 (-4.13%)
TTWO : 109.47 (-1.35%)
DXC : 25.30 (-3.36%)
NGVT : 48.67 (-4.10%)
SMMT : 1.40 (-2.43%)
KNSL : 127.59 (-2.20%)
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies...

MTFB : 0.10 (-4.63%)
SMMT : 1.40 (-2.43%)
CDTX : 2.90 (+0.69%)
CFRX : 9.93 (-9.15%)
ETTX : 5.02 (+0.28%)
ITRM : 2.93 (-6.98%)
MLNT : 0.4400 (-12.00%)
NBRV : 1.37 (-2.84%)
PRTK : 4.32 (+20.00%)
SCYX : 0.97 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SMMT with:

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

2nd Resistance Point 1.45
1st Resistance Point 1.43
Last Price 1.40
1st Support Level 1.37
2nd Support Level 1.33

See More

52-Week High 2.46
Fibonacci 61.8% 1.95
Fibonacci 50% 1.80
Fibonacci 38.2% 1.64
Last Price 1.40
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar